Lonza Group AG LONN:SIX; LO3:FSE; LZAGF:OTCPK

Notable Quotes

"If the data from the PRESERVE trial are positive, NEO may be able to enter partnership in the regenerative medicine space." (4/22/14) NeoStem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More�>

"ARNI's onapristone could legitimately be considered a pipeline in a single product." (4/22/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More�>

"DMPI's VAL-083 is a first-in-class small-molecule chemotherapeutic." (4/17/14) DelMar Pharmaceuticals Inc. - The Life Sciences Report Interview with Grant Zeng More�>

"CUR's science is cutting edge, and of a very high quality." (4/22/14) Neuralstem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More�>

"There is great potential for NEO to grow in the future." (4/17/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More�>

Companies

Lonza Group AG

TICKER: LONN:SIX; LO3:FSE; LZAGF:OTCPK

Would you like more information on this company?

First Name *

Last Name

Email *

Phone

* Required

In addition, I would like to receive The Life Sciences Report Newsletter

Fact sheets, annual reports, webinars, CEO interviews and more, may be available for this company. Fill out this form and your contact information will be shared with this company to provide you with additional information.